ESR1 and breast carcinoma: More recently, Razavi and colleagues reported that mutations in components of the mitogen-activated protein kinase (MAPK) pathway and the ER transcriptional program, found in approximately 20% of ER+ breast cancers, are associated with shorter response to antiestrogen therapy8.